Sector: MedicalPONIARD PHARMACEUTIC (NASDAQ: PARD)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 214 |
Technical : | 39 |
Performance : | 139 |
Overall: | 120 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 198 |
Technical : | 83 |
Performance : | 261 |
Overall: | 211 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 195 |
Technical : | 46 |
Performance : | 224 |
Overall: | 172 |
Number of Stocks: | 306 |
Headlines
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Nov 17, 2009 12:52 PM | PARD
- Movers and downers in the market for Monday the 16th
Nov 16, 2009 03:00 PM | ADY, ALKS, APOL, BMY, IBKC, INTC
- BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
Nov 16, 2009 11:56 AM | ALKS, CRL, CRXX, CYTX, HGSI, HHS
- Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint
Nov 16, 2009 07:03 AM | PARD
- Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
Nov 15, 2009 07:11 PM | PARD
- Semi-Annual Changes to the NASDAQ Biotechnology Index
Nov 13, 2009 08:02 PM | CSKI, HITK, NDAQ, PARD, SIGA, SPPI
- Investing In The Biotech Sector: Here’s An Easy Way To Profit From Biotech Stocks
Nov 11, 2009 10:44 AM | ARIA, BBI, BMRN, BMY, CELG, IMGN
- Poniard Pharmaceuticals to Present Updated Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and Final Phase 1 Cardiac Safety Trial Results
Nov 10, 2009 08:03 AM | PARD
- Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Nov 03, 2009 04:05 PM | PARD
- Poniard Pharmaceuticals to Host Third Quarter 2009 Financial Results Conference Call on November 3
Oct 27, 2009 08:31 AM | PARD
- Poniard Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
Aug 20, 2009 06:05 AM | PARD
- Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Aug 04, 2009 04:01 PM | PARD
- Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
Jul 29, 2009 08:32 AM | PARD
- Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Jul 28, 2009 01:06 PM | PARD
- Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Jul 21, 2009 08:02 AM | PARD
- Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
Jul 09, 2009 08:02 AM | PARD
- Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Jun 05, 2009 08:31 AM | PARD
- Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
May 28, 2009 08:03 AM | PARD
- Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
May 28, 2009 08:01 AM | PARD
- Poniard Pharmaceuticals Files Shelf Registration
May 15, 2009 08:00 AM | PARD
- Form 4 PONIARD PHARMACEUTICALS, For: Nov 15 Filed by: JACKSON MICHAEL K (10K)
Nov 17, 2009 07:43 PM
- Form 4 STEINMETZ MICHAEL For: Nov 05 (10K)
Nov 09, 2009 07:41 PM
- Form 4 SIMON NICHOLAS J III For: Nov 05 (10K)
Nov 09, 2009 07:39 PM
- Form 4 MPM BIOVENTURES III QP For: Nov 05 (10K)
Nov 09, 2009 07:37 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Oct 06 Filed by: MARTELL RON (10K)
Oct 08, 2009 07:13 PM
- Form 4 WEAVER GREGORY L For: Aug 21 (10K)
Aug 21, 2009 01:43 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Jul 11 Filed by: LYONS GARY A (10K)
Jul 14, 2009 03:21 PM
- Form 4 PONIARD PHARMACEUTICALS, For: Jul 07 Filed by: LYONS GARY A (10K)
Jul 09, 2009 07:48 PM
- Form 3 PONIARD PHARMACEUTICALS, For: Jul 07 Filed by: LYONS GARY A (10K)
Jul 09, 2009 07:47 PM
- Form 4 JACKSON MICHAEL K For: Jun 02 (10K)
Jun 03, 2009 05:02 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
PARD
|
Compare to S&P
|
| YTD |
292.75 %
|
224.42 %
|
| 4 Weeks |
10.34 %
|
9.75 %
|
| 12 Weeks |
6.01 %
|
-0.52 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -3.57 %
|
|
EPS Growth in Last Year: 19.44 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
